Sponsored Supplement

Challenges, Evidence, and Treatment Options for Anticoagulation of Obese and Morbidly Obese Patients with Nonvalvular Atrial Fibrillation (NVAF)

Publish date: January 23, 2020
Sponsored by Janssen Pharmaceuticals, Inc.

 

In this supplement, Paul P. Dobesh, PharmD, examines NVAF in the obese and morbidly obese patient population with a focus on anticoagulant treatment options. Topics include:

  • Understanding the obesity risk in patients with NVAF
  • Challenges of anticoagulation with warfarin in patients with obesity
  • NVAF patients with obesity

Click here to access the supplement.

January 2020 cp-127604v1

Recommended Reading

Medscape survey points to generational differences in physician burnout
MDedge Cardiology
ACP maps two potential paths to universal health care
MDedge Cardiology
Common drug with lots of surprising side effects
MDedge Cardiology
Renal denervation rebounds
MDedge Cardiology
Washington state patient is first U.S. case of novel coronavirus
MDedge Cardiology
Cardiac biomarkers refine antihypertensive drug initiation decisions
MDedge Cardiology
Why STEMI patients benefit from PCI of nonculprit lesions
MDedge Cardiology
Redo PCI or CABG, left main patients pay a price: EXCEL
MDedge Cardiology
Carbs, fat, and mortality: Types matter more than levels
MDedge Cardiology
Actor Alan Alda discusses using empathy as an antidote to burnout
MDedge Cardiology